We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Novel Solution Used to Store Donated Blood Platelets

By LabMedica International staff writers
Posted on 28 Dec 2009
A platelet additive solution, in combination with human plasma, is being used to store donated platelets, a vital blood component used to prevent or treat bleeding.

The InterSol additive is an isotonic solution designed to replace a portion of the plasma used in the storage of leuko-reduced apheresis platelets, under standard blood banking conditions. More...
The platelets can be stored in a mixture of up to 65% InterSol solution and 35% human plasma, which can then be used for other therapeutic purposes. There is no direct therapeutic effect to be expected from the formulation, and the solution should never be infused directly into a patient. The InterSol solution is provided as a 500 ml sterile and nonpyrogenic solution in a non-PVC plastic container, with a sterile fluid path. Platelets prepared with the solution may be stored for up to 5 days at 20 °C to 24 °C, with continuous agitation.

The solution contains constituents that are naturally occurring components present in many cellular systems: sodium acetate as a nutrient, sodium citrate to prevent platelet clumping and activation, sodium phosphate for buffering, and sodium chloride for osmolarity. The InterSol solution does not have a pharmacological effect in vivo, but rather acts to provide the appropriate environment and nutrients in lieu of a portion of the plasma normally used for the storage of platelets. The InterSol solution is a product of Fenwal Blood Technologies (Lake Zurich, IL, USA), and has been approved for use by the U.S. Food and Drug Administration exclusively with platelets collected using the Fenwal Amicus separator, a medical device that collects platelets and other blood components from eligible donors.

"FDA approval for the InterSol solution is an exciting milestone for Fenwal and represents our collaboration with customers, industry, and scientific leaders to introduce new ways to collect, process, and store blood for transfusion,” said William H. Cork, Fenwal senior vice president and chief technology officer (CTO).

Refrigerated platelets have better in vitro function than those stored at room temperature, but once transfused, they are rapidly cleared from the circulation. In 1981, platelet storage at room temperature was extended from 3 days to 5 days due to improved platelet storage bags that allowed more efficient gas exchange. However, with the extended storage at room temperature, bacterial proliferation became a significant problem and an increased number of platelet transfusion-associated sepsis reactions occur.

Related Links:
Fenwal Blood Technologies




Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Ketosis and DKA Test
D-3-Hydroxybutyrate (Ranbut) Assay
Pipette
Accumax Smart Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The simple blood marker can predict which lymphoma patients will benefit most from CAR T-cell therapy (Photo courtesy of Shutterstock)

Routine Blood Test Can Predict Who Benefits Most from CAR T-Cell Therapy

CAR T-cell therapy has transformed treatment for patients with relapsed or treatment-resistant non-Hodgkin lymphoma, but many patients eventually relapse despite an initial response. Clinicians currently... Read more

Pathology

view channel
Image: Determining EG spiked into medicinal syrups: Zoomed-in images of the pads on the strips are shown. The red boxes show where the blue color on the pad could be seen when visually observed (Arman, B.Y., Legge, I., Walsby-Tickle, J. et al. https://doi.org/10.1038/s41598-025-26670-1)

Rapid Low-Cost Tests Can Prevent Child Deaths from Contaminated Medicinal Syrups

Medicinal syrups contaminated with toxic chemicals have caused the deaths of hundreds of children worldwide, exposing a critical gap in how these products are tested before reaching patients.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.